Tobramycin Nebulization Guidelines for Cystic Fibrosis

Primary Indication

The European Respiratory Society recommends nebulized tobramycin for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients aged ≥6 years, administered at 300 mg twice daily in alternating 28-day on/28-day off cycles 1, 2
All patients with cystic fibrosis who have chronic P. aeruginosa infection should receive nebulized tobramycin, regardless of lung function status 1, 2

The standard dose is 300 mg twice daily via nebulization, with alternative formulations including 80 mg twice daily or 160 mg twice daily, which are safe but less effective 1
Intermittent dosing with 28 days on treatment, followed by 28 days off treatment, in alternating cycles reduces resistance development to 13-25% 1, 3, 4, 5

Patients must receive a bronchodilator before nebulized tobramycin to prevent bronchospasm, which is the major side effect 1, 2
Perform airway clearance techniques before nebulization to improve drug delivery 6
Use a nebulizer producing particles of 2-5 μm diameter to reach smaller bronchioles 1, 4

Caution is needed when patients receive intravenous aminoglycosides in addition to high-dose aerosolized tobramycin—serum tobramycin levels should be monitored 1, 3, 4
No evidence of renal toxicity or auditory toxicity when inhaled tobramycin is used alone 1, 2

Resistance to tobramycin may develop but does not appear clinically important 1
Regular monitoring of sputum cultures is essential to assess bacterial density and resistance 5, 7

The European Respiratory Society recommends performing airway clearance techniques before nebulization to improve drug delivery to infected areas, as cystic fibrosis mucus plugs can bind aminoglycosides and reduce efficacy 8
The European Respiratory Society suggests that IV administration is preferred for acute pulmonary exacerbations, and nebulized tobramycin during acute exacerbations shows low efficacy 8, 9

The European Respiratory Society found that nebulized tobramycin during acute exacerbations shows low efficacy, and IV administration is preferred for acute pulmonary exacerbations 8, 9

The European Respiratory Society reports that resistance may develop but susceptibility is often regained during the 28-day off-treatment periods 10
The European Respiratory Society notes that increased isolation of Candida albicans and Aspergillus species has been reported in the treatment group compared to placebo, though clinical significance is unclear 9

The European Respiratory Journal recommends ensuring isotonic solutions are used, as hypotonic or hypertonic solutions can cause bronchoconstriction and inflammation 11
The European Respiratory Journal also notes that for colistin (alternative agent), the dose is 2 million units twice daily dissolved in 3 mL of isotonic solution, not the tobramycin dose, and higher doses of tobramycin (600 mg three times daily) have shown efficacy but are not standard practice 11

The European Respiratory Journal reports that higher doses (600 mg three times daily) of nebulized tobramycin have shown efficacy but are not standard practice 11

Intravenous tobramycin formulations must not be used for inhalation because their preservatives and inappropriate osmolality/pH provoke bronchospasm and airway inflammation. 12

For patients aged ≥ 6 years with chronic Pseudomonas aeruginosa infection, the FDA‑approved Tobramycin Solution for Inhalation (TSI/TOBI®) is given at 300 mg twice daily via a PARI LC PLUS nebulizer in alternating 28‑day on / 28‑day off cycles. 13

Grade A (strong) recommendation: In patients aged ≥ 6 years with moderate‑to‑severe cystic fibrosis lung disease and persistent P. aeruginosa infection, inhaled tobramycin improves lung function, enhances quality of life, and reduces pulmonary exacerbations with high certainty of substantial benefit. 13
Grade B recommendation: In patients aged ≥ 6 years with mild cystic fibrosis lung disease and persistent P. aeruginosa infection, inhaled tobramycin reduces exacerbations with moderate certainty of benefit. 13